Argent BioPharma (ASX:RGT) and AusCann Group Holdings signed a strategic heads of agreement to advance cannabinoid-based pharmaceutical development through the exchange of proprietary datasets and regulatory expertise, according to a Tuesday Australian bourse filing.
AusCann will license Argent BioPharma's CannEpil CMC and Dossier specifically for non-epilepsy-related pharmaceutical programs.
The companies will also gain access to AusCann's proprietary self-emulsifying hard-shell capsule formulation, Neuvis, including access to pharmacokinetic and pharmacodynamic data.
The firms will also establish a joint steering committee to coordinate research and development efforts as well as optimize regulatory strategies.
The agreement also includes a deferred licensing fee structure, with royalties on pharmaceutical products developed using jointly leveraged data, research and development, or assets.
Financial terms were not disclosed.
Argent BioPharma's shares were down almost 3% in recent Tuesday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。